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Key messages
 ► There is intense interest in discovering systemic bio-
markers that may relate to important patient related 
outcomes (PRO) in patients with COPD.
 ► Using data and biological samples prospectively 
collected in the Study to Understand Mortality and 
MorbidITy (SUMMIT) study in 1,673 COPD patients 
with heightened cardiovascular risk the systemic 
levels of C-reactive protein (CRP), fibrinogen, sur-
factant protein-D (SPD), soluble receptor of glycation 
end-product (sRAGE) and club cell protein 16 (CC16) 
were related to rate of decline of the forced expira-
tory volume in the 1st second (FEV1), exacerbations, 
hospitalizations and mortality.
 ► We found no relationship between serum levels of 
these 5 biomarkers and rate of FEV1 decline (ml/
year) and COPD exacerbations and hospitalizations. 
The serum levels of CRP and fibrinogen, but not 
sRAGE, SPD or CC16 were related to increased risk 
of death. These results cast doubts about the clinical 
usefulness of the systemic levels of these proteins 
as surrogate markers of COPD related outcomes.
Strengths
 ► The relatively large sample size and multi-centre 
nature of the study overcome the usual limitations of 
smaller trials conducted in a single center.
 ► The patients included had a careful clinical, func-
tional and biological characterization. In addition, the 
study had a prospective design, significant follow-up 
time and a clinical adjudicating committee that vali-
dated the outcomes.
 ► The selections of biomarkers was based on previ-
ous studies suggesting a relationship between those 
proteins and outcomes.
AbstrAct
rationale Systemic levels of C reactive protein (CRP), 
surfactant protein D (SPD), fibrinogen, soluble receptor 
of activated glycogen end-product (sRAGE) and club cell 
protein 16 (CC-16) have been associated with chronic 
obstructive pulmonary disease (COPD) outcomes. However, 
they require validation in different cohorts.
Objectives Relate systemic levels of those proteins 
to forced expiratory volume in 1 s (FEV1) decline, 
exacerbations, hospitalisations and mortality in COPD 
patients (FEV1 of ≥50 and ≤70% predicted) and heightened 
cardiovascular risk in a substudy of the Study to 
Understand Mortality and MorbidITy trial.
Methods Participants were randomised to daily 
inhalations of placebo, vilanterol 25 µg (VI), fluticasone 
furoate 100 µg (FF) or their combination (VI 25/FF 100) 
and followed quarterly until 1000 deaths in the overall 16 
485 participants occurred. Biomarker blood samples were 
available from 1673 patients. The FEV1 decline (mL/year), 
COPD exacerbations, hospitalisations and death were 
determined. Associations between biomarker levels and 
outcomes were adjusted by age and gender.
results Systemic levels of CC-16, CRP, sRAGE, SPD and 
fibrinogen did not relate to baseline FEV1, FEV1 decline, 
exacerbations or hospitalisations. Fibrinogen and CRP were 
related to mortality over a median follow-up of 2.3 years. 
Only the CC-16 changed with study therapy (VI, FF and FF/
VI, p<0.01) at 3 months.
conclusions In COPD, systemic levels of CC-16, CRP, 
sRAGE, SPD and fibrinogen were not associated with 
FEV1 decline, exacerbations or hospitalisations. These 
results cast doubts about the clinical usefulness of the 
systemic levels of these proteins as surrogate markers of 
these COPD outcomes. The study confirms that CRP and 
fibrinogen are associated with increased risk of death in 
patients with COPD.
trial registration number NCT01313676.
IntrOductIOn
Chronic obstructive pulmonary disease 
(COPD) is an important cause of morbidity 
and mortality worldwide.1 Accurate 
prediction of outcomes such as rate of lung 
function decline, exacerbations, healthcare 
utilisation of resources and risk of death are 
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Limitations
 ► The SUMMIT study was an event-driven design and as such not all 
patients were followed over a period of several years.
 ► An assumption was made that a few (or possibly only one) biomark-
ers would be valid for all COPD patients. Given the heterogeneity of 
patients with COPD, this assumption may not be right.
important because it helps identify patients in whom the 
implementation of therapeutic measures could improve 
those outcomes.2 COPD is also a complex and heteroge-
neous disease at the genetic, cellular and molecular level, 
and therefore, it is likely that the use of biomarkers that 
reflect diverse pathobiological pathways could help assess 
multiple dimensions of disease progression that could be 
modulated with specific therapeutic agents.3
Several systemic biomarkers, including C reactive 
protein (CRP), fibrinogen and surfactant protein D 
(SPD) have been associated with increased risk of death 
in patients with COPD.4–8 However, their relationship 
to other outcomes such as rate of decline of the forced 
expiratory volume in 1 s (FEV1) of a forced expiratory 
manoeuvre, exacerbations and hospitalisations remains 
unclear.9 10 The serum concentration of club cell protein 
16 (CC-16) was inversely related to rate of FEV1 decline 
in observational studies,11 in pharmacological trials 
of patients with COPD12 and in smokers without clin-
ical airflow limitation.13 The serum levels of soluble 
receptor of activated glycogen end-product (sRAGE) 
relate inversely to progression of emphysema,14 as 
determined by serially repeated CT of the lungs. In 
addition, genome-wide association studies (GWAS) 
do support the increased prevalence of single nucleo-
tide polymorphisms associated to the RAGE,15 SPD and 
CC-16 genes.16 Importantly, the systemic baseline levels 
of troponin determined in the patients participating in 
the biomarker component of the Study to Understand 
Mortality and MorbidITy (SUMMIT) trial were highly 
predictive of subsequent cardiovascular (CV) events and 
death in this cohort.17
Based on these findings, we hypothesised that the 
serum levels of one or more of CC-16, CRP, sRAGE, SPD 
and fibrinogen would relate to the following outcomes: 
rate of FEV1 decline, exacerbations of COPD, hospital-
isations due to these episodes and the risk of death in 
patients with COPD. We tested this hypothesis using data 
and biological samples prospectively collected in the 
subset of patients recruited in the USA who participated 
in the SUMMIT study. SUMMIT was an event-driven 
study that assessed the efficacy and safety of inhaled corti-
costeroids (ICSs) and long-acting beta agonists (LABA) 
in COPD patients with heightened CV risk. In the subset 
of patients, serum samples were taken at baseline and 
3 months after randomisation, enabling us to also test 
whether pharmacotherapy modulated the serum levels 
of these biomarkers.
MethOds
study design and study population
SUMMIT was a prospective, multicentre, international 
randomised controlled trial to determine whether treat-
ment with the inhaled LABA vilanterol (VI), the ICS 
fluticasone furoate (FF) or both in combination could 
improve clinical outcomes in patients with moderate 
COPD and increased CV risk. Details regarding study 
design and its primary results have been previously 
published.18 19 In brief, participants included former or 
current smokers (≥10 pack-years) between 40 and 80 
years of age, with a history of COPD and a postbroncho-
dilator FEV1 to forced vital capacity ≤0.70 and an FEV1 
≥50% and ≤70% of predicted. They had a score ≥2 on 
the modified Medical Research Council dyspnoea scale. 
Patients were additionally required to have a history, or be 
at increased risk, of CV disease defined as coronary artery 
or peripheral arterial disease, prior stroke or myocardial 
infarction, or diabetes mellitus with target organ disease. 
Patients were also included if they had increased CV risk 
defined as being ≥60 years and receiving medications for 
two or more of the following: hypercholesterolaemia, 
hypertension, diabetes mellitus or peripheral vascular 
disease. While ICSs and LABA treatments were discon-
tinued before study entry, other COPD medications were 
permitted during the trial. Participants were randomly 
allocated to one of four treatments: placebo, FF (100 
µg), VI (25 µg) or their combination (FF/VI, 100/25 
µg) inhaled once daily as a dry powder. Of the total of 
16 485 patients who participated in SUMMIT, 1673 of 
those enrolled in the USA had blood samples analysed 
for this biomarker substudy. All patients provided written 
informed consent. The study is registered on  Clinical-
Trials. gov.
Patient and public involvement
Patients were not involved in the design, conduct or 
interpretation of the study.
Measurements and endpoints
On-treatment spirometry was performed following 
the European Respiratory Society/American Thoracic 
Society guidelines. Spirometric reference values were 
those of National Health and Nutrition Examination 
Survey.20 On-treatment COPD exacerbations requiring 
treatment with antibiotics and/or oral corticosteroids 
were recorded as moderate exacerbations, and those 
requiring hospitalisation were recorded as severe. 
On-treatment and post-treatment deaths were adjudi-
cated for cause by an endpoint committee.19
biomarkers
Blood samples were collected at baseline and 3 months 
postrandomisation. Samples were stored at –80°C until 
analysed. SPD, CC-16 and sRAGE were measured in 
serum samples. Fibrinogen and CRP (high-sensitivity 
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Figure 1 CONSORT diagram of the patients included in the systemic biomarker study completed only in the USA, as part 
of the SUMMIT international trial. CC-16, club cell protein 16; CONSORT, Consolidated Standards of Reporting Trials; CRP, C 
reactive protein; SPD, surfactant protein D; sRAGE, soluble receptor of activated glycogen end-product.
methods) were measured in plasma samples. All protein 
biomarkers were measured by validated immunoassays. 
Concentrations below lower limit of detection (LLD) 
were imputed to ½×LLD.
statistical analysis
To examine the effect of treatment on the change in 
biomarker concentrations between baseline and 3 
months, analyses of covariance were performed using the 
covariates of baseline biomarker concentration, age and 
gender. As all biomarkers except fibrinogen had posi-
tively skewed distributions, these were log transformed, 
and the changes were expressed as ratios, and geometric 
means presented rather than arithmetic means.
The biomarker concentrations were divided into 
groups according to tertiles at baseline and are presented 
in online supplementary table 1. To explore whether the 
biomarker concentrations affected rate of decline in 
FEV1, random coefficients models were fitted with terms 
of age, gender, baseline FEV1, time, treatment, treatment 
by time, baseline biomarker tertile groups and baseline 
biomarker tertile groups by time, with subjects fitted as a 
random effect. Associations between baseline biomarker 
tertile groups and endpoints including all-cause mortality, 
CV death, moderate or severe exacerbations and severe 
exacerbations were modelled using Cox proportional 
hazards including terms for age, gender and study treat-
ment and also previous exacerbation history for the exac-
erbation endpoints.
Correlations between variables of interest were 
explored using Pearson’s correlation coefficient.
Two-sided tests were performed post hoc at the 0.05 
level of significance, using SAS V.9.4. All p values are 
nominal, as no adjustment was made for multiple 
comparisons.
results
clinical data
The published primary results of SUMMIT showed that 
there was no effect of any of the therapies on mortality, 
the primary outcome.19 The Consolidated Standards 
of Reporting Trials diagram of the SUMMIT systemic 
biomarker substudy enrolled in the USA is shown in 
figure 1. Of the 16 485 worldwide patients participating 
in SUMMIT, 1673 recruited in the USA had biomarker 
data at baseline.
The clinical characteristics of the patients included in 
the study and those from the general SUMMIT popu-
lation are shown in table 1. Most characteristics were 
similar in both groups, except for the biomarker popula-
tion having more females, higher body mass index, fewer 
COPD exacerbations in the year prior to the study and 
some differences in CV history and CV therapy. In the 
biomarker substudy, the average age was 66 years, 62% 
of the patients were male and 49% were smoking at the 
time of enrolment. By design, they had moderate airflow 
limitation by the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) criteria (FEV1 60% predicted) and 
had significant CV disease or risk. Patients were followed 
for mortality for a median of 2 years and 3 months and 
for all on-treatment endpoints for a median of 18 months 
and an average of seven spirometric measurements over 
this time.
effect of treatment on biomarker concentration at 3 months
Inhaled VI, FF and the combination resulted in a 6%–9% 
reduction in CC-16 serum levels as is shown in online 
supplementary table 2 (p<0.01 for all three compared 
with placebo). However, there was no effect of the 
inhaled therapy on systemic levels of CRP, sRAGE, SPD 
and fibrinogen when compared with placebo (online 
supplementary table 3).
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Table 1 Demographic characteristics of the patients 
included in the biomarker substudy conducted in the USA 
and that of the worldwide participants
Biomarker 
substudy
SUMMIT 
population
n=1673 n=16 485
Age, years 66 (8) 65 (8)
Women 635 (38%) 4196 (25%)
BMI, kg/m2 31 (7) 28 (6)
Smoking status
  Current smoker 828 (49%) 7678 (47%)
  Smoking history (pack-years) 52 (29) 41 (24)
Respiratory status
  Postbronchodilator FEV1 (L) 1.7 (0.4) 1.7 (0.4)
  Predicted postbronchodilator FEV1 
(%)
59 (7) 60 (6)
Exacerbations in 12 months before 
study
  0 1215 (73%) 10 021 (61%)
  1 290 (17%) 4020 (24%)
  2+ 168 (10%) 2444 (15%)
Cardiovascular inclusion criteria
Manifest disease
  Coronary artery disease 818 (49%) 8379 (51%)
  Peripheral arterial disease 384 (23%) 3145 (19%)
  Previous stroke 172 (10%) 1595 (10%)
  Previous myocardial infarction 413 (25%) 2774 (17%)
  Diabetes with target organ disease 226 (14%) 1503 (9%)
At risk
  Hypercholesterolaemia 1072 (64%) 8479 (51%)
  Hypertension 1166 (70%) 11 478 (70%)
  Diabetes mellitus 447 (27%) 3480 (21%)
  Peripheral arterial disease 106 (6%) 1154 (7%)
Concomitant medications
  Antiplatelet 1081 (65%) 8517 (52%)
  Beta-blocker 787 (47%) 5667 (34%)
  ACE inhibitor 779 (47%) 7655 (46%)
  Statin 1263 (75%) 10 721 (65%)
  Long-acting muscarinic antagonist 168 (10%) 818 (5%)
  Xanthine (including theophylline) 78 (5%) 3719 (23%)
Treatment allocation
  Placebo 439 (26%) 4111 (25%)
  Fluticasone furoate 415 (25%) 4135 (25%)
  Vilanterol 416 (25%) 4118 (25%)
  Combination therapy 403 (24%) 4121 (25%)
Continuous variables are mean (SD); categorical variables are n and 
(%).
BMI, body mass index; FEV1, forced expiratory volume in 1 s;SUMMIT, 
Study to Understand Mortality and MorbidITy.
Figure 2 Relationship between baseline biomarker 
concentration and percent predicted FEV1. CC-16, club cell 
protein 16; CRP, C reactive protein; FEV1, forced expiratory 
volume in 1 s; SPD, surfactant protein D; sRAGE, soluble 
receptor of activated glycogen end-product.
baseline biomarker data and outcomes
There was no relationship between baseline levels of 
CC-16, CRP, sRAGE, SPD and fibrinogen and baseline 
FEV1 expressed as % of predicted normal value (figure 2). 
The rate of decline in FEV1 was not different between 
the baseline tertile groups for any of the biomarkers 
(table 2). There was no association between any of the 
biomarker concentrations and the risk of a moderate or 
severe COPD exacerbation (online supplementary figure 
1) or a hospitalised exacerbation (online supplementary 
figure 2).
Higher systemic levels of CRP and fibrinogen were 
associated with higher risk of all-cause mortality as is 
shown in figure 3. The number of deaths by any cause 
for CRP were: highest tertile group 36 (7%) versus lowest 
tertile group 22 (4%), HR 1.91; middle tertile group 
35 (6%) versus lowest tertile group 22 (4%), HR 1.70; 
for fibrinogen they were highest group 43 (8%) versus 
lowest group 21 (4%), HR 2.24; middle group 24 (5%) 
versus lowest group 21 (4%), HR 1.24. There were no 
apparent relationships between CC-16, sRAGE and SPD 
and all-cause mortality (online supplementary figure 3) 
or with any of the measured biomarkers and CV death 
(online supplementary figure 4).
dIscussIOn
This prospective study of COPD patients with moderate 
airflow limitation and heightened CV risk provides 
two novel findings. First, the systemic levels of the five 
cytokines (CC-16, sRAGE, SPD, CRP and fibrinogen S), 
selected because of previous studies suggesting their 
potential value as predictors of outcomes in COPD, 
were unrelated to rate of FEV1 decline, exacerbation 
frequency and hospitalisations in these patients. The 
systemic levels of CRP and fibrinogen were associated 
with increased risk of all-cause mortality, confirming the 
predictive value for this outcome reported by others. 
Second, compared with placebo, once-daily inhalation of 
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Table 2 Rate of FEV1 decline (mL/year) by systemic biomarker tertile groups
Number of patients in analysis*
Lowest tertile group Middle tertile group Highest tertile group
Mean rate of decline (mL/year) (SE)
CRP† 1462 –38 (7) –40 (7) –33 (7)
sRAGE† 1454 –37 (7) –37 (7) –36 (7)
SPD† 1461 –30 (7) –33 (7) –48 (7)
Fibrinogen† 1410 –39 (7) –35 (7) –37 (8)
CC-16‡
 
  Placebo
  FF 100
  VI 25
  FF/VI 100/25
371
365
362
363
33 (15)
32 (15)
62 (15)
23 (13)
57 (14)
47 (15)
41 (15)
37 (14)
27 (15)
21 (14)
56 (15)
11 (13)
CC-16, club cell protein 16; CRP, C reactive protein; FEV1, forced expiratory volume in 1 s; FF, fluticasone furoate; SPD, surfactant protein D; 
sRAGE, soluble receptor of activated glycogen end-product; VI, vilanterol.
*To be included in the analysis a patient needed to have an on-treatment FEV1 measurement and the baseline biomarker measurement.
†All four treatment arms (placebo, FF, VI and FF/VI): random coefficients model fitted with terms of age, gender, baseline FEV1, time, 
treatment, treatment by time, baseline biomarker tertile groups and baseline biomarker tertile groups by time.
‡Presented by arm, because CC-16 concentrations at 3 months were affected by treatment (online supplementary table S2): random 
coefficients model fitted with terms of age, gender, baseline FEV1, time, baseline CC-16 tertile groups and baseline CC-16 tertile groups by 
time.
Figure 3 Kaplan–Meier plots of time to death by tertile groups for CRP and fibrinogen. HRs from Cox proportional hazard 
model adjusted for treatment, age and gender. Biomarker tertile group: Low in black colour. Middle in orange colour. High in 
green colour. CRP, C reactive protein.
VI, FF and the combination resulted in small but signif-
icant decreases in the serum levels of CC-16, but not in 
the other biomarkers.
Previous studies
There has been a growing interest in the field of 
biomarkers in COPD as a tool to predict outcomes or as 
marker of them, thus making them theoretically useful as 
surrogate markers of response for therapeutic interven-
tions.9 10 21–23 CRP has been the best studied biomarker in 
COPD. Most studies found that CRP levels are elevated 
in these patients,6 24 25 as compared with non-smokers 
and smokers without airflow obstruction, but the rela-
tionship between CRP levels and exacerbations as well 
as mortality remain inconsistent.25 26 Studies have also 
not consistently shown a relationship between CRP and 
rate of lung function decline.11 Similarly, several studies 
have documented a relationship between blood levels of 
fibrinogen and risk of death in patients in general27 and 
COPD in particular.5 7 28 Integration of all the data avail-
able by the COPD Biomarker Qualification Consortium 
initiative resulted in US Food and Drug Administration 
approval of this biomarker to stratify patients for studies 
of COPD.7 There is less information regarding the rela-
tionship between systemic levels of fibrinogen and other 
important outcomes in COPD, such as rate of lung func-
tion decline and hospitalisations.29
Of the many other systemic biomarkers studied in 
patients with COPD, the circulating levels of CC-16, SPD 
and sRAGE have shown the strongest association between 
their levels and COPD outcomes.15 30–34 CC-16 levels have 
been found to be reduced in patients with COPD and are 
inversely associated with rate of decline of FEV1 in some 
studies.13 35 The lung-derived protein SPD, however, is 
associated with presence of pulmonary inflammation 
and is elevated in smokers with or without COPD.31 The 
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systemic levels of sRAGE are inversely related to the degree 
of emphysema as determined by CT scans of the lungs,14 
while GWAS have documented the increased prevalence 
of single nucleotide polymorphisms associated with the 
RAGE gene.15 All of these proteins have been suggested 
as potential biomarkers of COPD outcomes, but not all of 
them have been studied simultaneously and prospectively 
while evaluating the effect of therapy on their levels.
Although statistically significant associations are 
important for studies and research, the ideal biomarker 
for the clinician is useful primarily if it helps a single 
patient, the one in front of the provider. So if a biomarker 
is to reach the bedside, it has to have a strong association 
with an outcome and provide information above and 
beyond that obtained by good clinical evaluation.
current findings
The prospective SUMMIT study provided the opportu-
nity to test the predictive ability of the selected circu-
lating proteins on important respiratory outcomes. To 
our disappointment, none of the systemic levels of the 
five circulating proteins studied related to rate of FEV1 
decline, exacerbations and hospitalisations (table 2, 
online supplementary figures 1 and 2). Although a true 
association might have been found if more patients 
had been recruited, this appears unlikely as several of 
the studies documenting an association between those 
biomarkers and the outcomes were smaller or similar in 
size to ours. In addition, it is known that the rate of FEV1 
decline is larger in patients with higher FEV1,
36 so if there 
was a relationship between any of the biomarkers selected 
and lung function decline, these moderately obstructed 
patients were the most likely individuals to have demon-
strated such an association. Furthermore, a biomarker 
is most useful when it can help clinicians in their prac-
tice usually with a single patient, and certainly, the lack 
of precision documented in this study renders them of 
limited use in everyday patient care. However, the asso-
ciation observed between systemic levels of CRP and 
fibrinogen with mortality in this study (figure 3) supports 
their validity as predictors of risk of death in general 
and in patients with heightened CV risk, as were those 
included in SUMMIT.37 38 We acknowledge that there 
were no measurements of these biomarkers during exac-
erbations, where the changes might identify or grade the 
severity of these events, as has been suggested before.39 
Importantly, the significant association observed between 
baseline serum levels of troponin and subsequent risk of 
CV events and death in this cohort17 indicates that meth-
odological issues or the study design and completion are 
unlikely to have influenced the results here reported.
The difference between the negative results in 
COPD-related outcomes in this study, and the positive 
ones reported by previous authors may relate primarily to 
the populations included in the different studies.6–8 11–15 
Whereas the majority of the positive results came from 
cohort studies such as ECLIPSE and COPDgene, which 
included patients with a wider range of lung function 
impairment, the population included in SUMMIT 
consisted of patients with a moderate degree of airflow 
limitation and heightened CV risk. However, for a 
biomarker to be useful in clinical practice, it has to help 
clinicians at any stage of the disease and most of all for 
patients with milder disease, such as those included in 
SUMMIT.
One potential use of biomarkers is their response to 
therapy specifically directed at the disease in question 
and if this change was associated to a modification in 
outcomes. In this study, the relative levels of CC-16 were 
decreased by the three active treatment arms of the study 
compared with placebo. The effects were small, likely of 
little clinical meaning, but nevertheless statistically signif-
icant (table S2). A decrease in CC-16 was not associated 
with FEV1 decline in this study, a fact that could have 
several explanations. First, that CC-16 bears little relation 
to FEV1 decline, as has been suggested by some studies,
12 
or second, that the small changes in serum levels of 
CC-16 carry little biological significance. However, 
the results do suggest that inhaled therapies may alter 
systemic levels of cytokines and that if associations with 
valid outcomes were to be found, one or more cytokines 
could be used as surrogate markers to evaluate effect of 
therapy. Interestingly, we found no effect of any of the 
therapies given in SUMMIT on CRP levels, providing 
contrast to the findings of an older study that demon-
strated reduced CRP levels after the administration of 
ICSs.40 Conversely, however, our findings are in agree-
ment with those of a further study, in which the adminis-
tration of inhaled tiotropium did not affect inflammatory 
markers in patients with COPD.41 Finally, the stability of 
the selected biomarkers over 3 months is consistent with 
data previously reported in ECLIPSE.42
strengths and limitations
The relatively large sample size and multicentre nature 
of the study, its careful clinical, functional and biological 
characterisation and its prospective design, follow-up 
time and clinical adjudicating committee are strengths 
of this study. However, there were several potential limi-
tations. First, the study had an event-driven design and as 
such not all patients were followed over a period of several 
years. However, with an average of 18 months of on-treat-
ment observation and of 27 months for mortality, the 
determination of two biosamples separated by 3 months 
and a mean number of 7 spirometric measurements per 
patient, we believe the observation time is sufficient for 
all of the outcomes selected. Second, the chosen panel of 
proteins did not include all possible biomarkers that have 
been suggested.9 43 However, the ones here measured 
included those that have the strongest support in the 
literature as being potentially applicable in clinical prac-
tice. Third, it could be argued that there was no deriv-
ative and validating cohort. However, this is customary 
for non-validated biomarkers, whereas in this study, 
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we compared validated clinical and serum biomarkers 
modelled on studies in the respiratory and CV arena. 
The main weakness is likely to be the assumption that 
a few (or possibly only one) biomarkers will be valid for 
all patients with COPD. Given the heterogeneity of the 
disease this is unlikely; however, we currently are unable 
to identify subgroups where specific biomarkers would be 
of particular value.
conclusions
In this substudy of the SUMMIT trial of patients with 
moderate COPD, the serum level of CC-16, sRAGE and 
SPD or their changes over 3 months were not predictive 
of rate of lung function decline and risk of exacerbations 
or hospitalisations. Although systemic levels of CRP and 
fibrinogen were associated with increased mortality risk, 
the levels were not associated with rate of FEV1 decline, 
exacerbations or hospitalisations. These results cast some 
doubts about the clinical usefulness of the systemic levels 
of CC-16, sRAGE and SPD as surrogate markers of disease 
in patients with moderate COPD.
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